ArticleEJNMMI research2025
Staging lung cancer: total-body PET/CT or whole-body PET/CT?
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTotal Body PET/CT is increasingly used in clinical practice, but its benefits for lung cancer staging are not fully established. This study aimed to evaluate the impact of Total Body PET/CT on lung cancer staging compared to traditional Whole-Body PET/CT.
resultsAmong the 763 patients, 289 (37.9%) had stage IV disease, with 96 (33.2%) showing limb metastases, including those in the lower limbs (legs) or also the upper limbs (arms). Compared to Whole-Body PET/CT, Total Body PET/CT detected additional metastases in 60.4% (58/96) of patients with limb metastases, representing 20.1% (58/289) of all stage IV patients. These included 96 bone and 43 muscle metastases. In patients with isolated limb metastases (n = 31), Total Body PET/CT detected additional metastases in 13 (41.9%) compared to Whole-Body PET/CT, altering tumor staging in only one patient (0.3% of stage IV patients). In those with multiple limb metastases (n = 65), Total Body PET/CT detected additional metastases in 45 (69.2%), but staging remained unchanged. Distal limb metastasis was strongly associated with concurrent bone (OR = 8.288, 95%CI: 3.642-18.861) and muscle metastases outside the limb (OR = 3.911, 95%CI: 1.624-9.417) (both P < 0.001). Additionally, Total Body PET/CT detected acute arthritis in 193 (25.3%) patients and benign lesions (e.g., varicose veins, neurogenic tumors, lipomas, fractures) in 68 (8.9%) compared to Whole-Body PET/CT.
conclusionWhole-Body imaging is sufficient to meet the clinical staging requirements for lung cancer. Although Total Body PET/CT detects more distal metastases in approximately 20% of stage IV lung cancer patients, it led to stage shift in only one patient and 0% change in the oncologic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.